iBio, Inc.
$1.97
▲
1.54%
2026-04-21 07:25:01
ibioinc.com
NCM: IBIO
Explore iBio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$70.3 M
Current Price
$1.97
52W High / Low
$3.82 / $0.56
Stock P/E
—
Book Value
$1.88
Dividend Yield
—
ROCE
-108.92%
ROE
-70.22%
Face Value
—
EPS
$-1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
20
Beta
1.36
Debt / Equity
4.33
Current Ratio
9.04
Quick Ratio
1.59
Forward P/E
-7.45
Price / Sales
248.71
Enterprise Value
$24.37 M
EV / EBITDA
-0.98
EV / Revenue
81.22
Rating
Strong Buy
Target Price
$5.37
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | LB Pharmaceuticals Inc | $31.67 | — | $875.16 M | — | -9.95% | -15.7% | $30.72 / $13.36 | $11.91 |
| 2. | Lisata Therapeutics, Inc. | $2.83 | — | $25.56 M | — | -124.1% | -75.53% | $5.07 / $1.81 | $1.68 |
| 3. | NewAmsterdam Pharma Company N.V. | $33.82 | — | $3.89 B | — | -33.02% | -28.29% | $42 / $15.82 | $5.97 |
| 4. | Edgewise Therapeutics, Inc. | $33.97 | — | $3.69 B | — | -36.44% | -34.19% | $35 / $12.15 | $4.92 |
| 5. | Forte Biosciences, Inc. | $34.43 | — | $674.68 M | — | -113.91% | -1.22% | $35.8 / $4.9 | $4.71 |
| 6. | Alzamend Neuro, Inc. | $1.11 | — | $4.26 M | — | -113.32% | -2.5% | $8.22 / $0.84 | $0.57 |
| 7. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0.1 M | 0.2 M | 0 M | 0.2 M | — |
| Operating Profit | -9.45 M | -5.95 M | -5.2 M | -4.88 M | -4.42 M | — |
| Net Profit | -8.99 M | -5.72 M | -5.16 M | -4.86 M | -4.36 M | — |
| EPS in Rs | -0.26 | -0.17 | -0.15 | -0.14 | -0.13 | -0.46 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.4 M | 0.23 M | 0 M | 1.88 M |
| Operating Profit | -18.6 M | -16.63 M | -29.34 M | -29.7 M |
| Net Profit | -18.38 M | -24.91 M | -65.01 M | -50.39 M |
| EPS in Rs | -0.53 | -0.72 | -1.88 | -1.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 23.18 M | 28.73 M | 41.21 M | 99.41 M |
| Total Liabilities | 8.3 M | 7.41 M | 25.83 M | 35.92 M |
| Equity | 14.88 M | 21.32 M | 15.38 M | 63.48 M |
| Current Assets | 9.72 M | 15.67 M | 26.26 M | 45.07 M |
| Current Liabilities | 6.11 M | 3.84 M | 22.11 M | 30.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -15.3 M | -18.55 M | -30.44 M | -37.48 M |
| Investing CF | 0.74 M | 0.91 M | 7.01 M | -5.13 M |
| Financing CF | 8.93 M | 24.49 M | 2.3 M | -6.12 M |
| Free CF | -15.32 M | -18.76 M | -36.17 M | -49.11 M |
| Capex | -0.02 M | -0.21 M | -5.74 M | -11.63 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 61.69% | -29.01% | — | — |
| Profit Margin % | -11069.78% | — | -2674.68% | — |
| Operating Margin % | -7392.89% | — | -1576.27% | — |
| Gross Margin % | — | — | 115.02% | — |
| EBITDA Margin % | -6231.56% | — | -1365.29% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-11-29 | 1:0.05 |
| 2022-10-10 | 1:0.04 |